These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33917431)

  • 1. Thrombocytopenia and Hemostatic Changes in Acute and Chronic Liver Disease: Pathophysiology, Clinical and Laboratory Features, and Management.
    Scharf RE
    J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33917431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
    Khemichian S; Terrault NA
    Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytopenia in Chronic Liver Disease and the Role of Thrombopoietin Agonists.
    Miller JB; Figueroa EJ; Haug RM; Shah NL
    Gastroenterol Hepatol (N Y); 2019 Jun; 15(6):326-332. PubMed ID: 31391802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombocytopenia in Chronic Liver Disease: New Management Strategies.
    Nilles KM; Flamm SL
    Clin Liver Dis; 2020 Aug; 24(3):437-451. PubMed ID: 32620282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Thrombocytopenia in Patients with Chronic Liver Disease.
    Saab S; Brown RS
    Dig Dis Sci; 2019 Oct; 64(10):2757-2768. PubMed ID: 31011942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
    Hidaka H; Kurosaki M; Tanaka H; Kudo M; Abiru S; Igura T; Ishikawa T; Seike M; Katsube T; Ochiai T; Kimura K; Fukuhara T; Kano T; Nagata T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1192-1200. PubMed ID: 30502505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag.
    Abdela J
    Clin Med Insights Blood Disord; 2019; 12():1179545X19875105. PubMed ID: 31673229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.
    Gallo P; Terracciani F; Di Pasquale G; Esposito M; Picardi A; Vespasiani-Gentilucci U
    World J Gastroenterol; 2022 Aug; 28(30):4061-4074. PubMed ID: 36157107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombocytopenia in chronic liver disease.
    Peck-Radosavljevic M
    Liver Int; 2017 Jun; 37(6):778-793. PubMed ID: 27860293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States.
    Dieterich DT; Bernstein D; Flamm S; Pockros PJ; Reau N
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1311-1322. PubMed ID: 32813292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?
    Olson SR; Koprowski S; Hum J; McCarty OJT; DeLoughery TG; Shatzel JJ
    Platelets; 2019; 30(6):796-798. PubMed ID: 30422039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of thrombocytopenia due to liver cirrhosis: a review.
    Hayashi H; Beppu T; Shirabe K; Maehara Y; Baba H
    World J Gastroenterol; 2014 Mar; 20(10):2595-605. PubMed ID: 24627595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathophysiology of thrombocytopenia in chronic liver disease.
    Mitchell O; Feldman DM; Diakow M; Sigal SH
    Hepat Med; 2016; 8():39-50. PubMed ID: 27186144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence.
    Qureshi K; Patel S; Meillier A
    Int J Hepatol; 2016; 2016():1802932. PubMed ID: 27800187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
    Xu H; Cai R
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
    [No Abstract]   [Full Text] [Related]  

  • 16. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching.
    Furuichi Y; Takeuchi H; Yoshimasu Y; Kasai Y; Abe M; Itoi T
    Hepatol Res; 2020 Sep; 50(9):1062-1070. PubMed ID: 32510789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Hemostasis in Chronic Liver Disease and Cirrhosis: What Did We Learn over the Past Decade?
    van Dievoet MA; Eeckhoudt S; Stephenne X
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32384725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
    Maan R; de Knegt RJ; Veldt BJ
    Drugs; 2015 Nov; 75(17):1981-92. PubMed ID: 26501978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Katsube T; Shimizu R; Fukuhara T; Kano T; Wajima T
    Clin Pharmacokinet; 2019 Nov; 58(11):1469-1482. PubMed ID: 31055790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.